NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Curi Bio

Curi Bio

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.curibio.com/

Last Round

Series B

Dec 2, 2025

Total Funding Raised

$24.4M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Curi Bio is a biotechnology company that provides a preclinical discovery platform combining human stem cells, systems, and data to accelerate the discovery of new medicines.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Biotech Equipment, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Subscription SaaS, Data as a Service

AI Layer

Application

Keywords

drug discoveryiPSCinduced pluripotent stem celltissue engineeringorgan-on-a-chippreclinical testing3D muscle tissuecontractile force measurementphenotypic screeningbiotech equipmenthigh-throughput screeningelectrophysiologycontract researchlab automationassay development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Curi Bio Comps

Public and private peers based on sector, stage, and business model.

Curi Bio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Curi Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 2, 2025
GrantAug 23, 2023
Series ADec 29, 2021

Key People

Founding team and executive leadership

Nicholas Geisse

Chief Executive Officer

Executive Team

Dongwook Kim

Chief Financial Officer

Executive Team

Curi Bio Investors

Notable investors and investment history

Curi Bio investors
InvestorRounds
Dynamk CapitalSeries A
UTC InvestmentSeries B, Series A
NIH RADxGrant
DS Asset ManagementSeries B, Series A
National Center for Advancing Translational SciencesGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 23, 2026

    Launched a commercially available HCM isogenic pair.

  • Mar 20, 2026

    Partnered with Battelle to commercialize NMJ assay technology.

Curi Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Curi Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Curi Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range58
Year Founded2015
Last FundingDec 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.